Palatin Technologies Presents Preclinical Data on MC4R-Selective Peptide Agonists at ObesityWeek® 2026
Palatin Technologies presented new preclinical data for its proprietary MC4R-selective peptide agonist programs at the ObesityWeek® 2026 conference.